Lyme Disease Underfunded: Why Research Is Still Too Slow
Diagnosis is still too slow
Treatment is often delayed
Research has not kept pace
Patients continue to suffer
Lyme disease is underfunded—and patients are paying the price.
Every day, clinicians see the pain, confusion, fatigue, and brain fog that disrupt patients’ lives. Delays in diagnosis and treatment are not just clinical challenges—they reflect systemic gaps in research and funding.
Awareness has improved. Progress has been made. But the pace remains nowhere near where it needs to be.
We are still too slow to diagnose. Too slow to treat. Too slow to research. Too slow to act.
The question of how we allocate resources for Lyme disease is not just a policy issue—it is an ethical one.
The Gap Between Need and Investment
Lyme disease is one of the most common vector-borne diseases in the United States, with estimates approaching half a million new cases each year—and that number continues to rise.
Underfunding reflects a mismatch between disease burden and research prioritization.
It contributes to a persistent education gap that leaves physicians and patients without answers.
Data from the National Institutes of Health (NIH) show that Lyme disease research receives a fraction of the funding allocated to other infectious and chronic conditions.
The Centers for Disease Control and Prevention (CDC) continues to document rising case numbers, yet research investment has not kept pace with clinical need.
The problem is not a lack of science. It is a lack of urgency.
What COVID-19 Showed Us About Research Speed
When the COVID-19 pandemic struck, the response was unprecedented. Research, diagnostics, vaccines, logistics, and public education were accelerated simultaneously.
Funding was mobilized. Barriers were reduced. Timelines that once took years were compressed into months.
The lesson was not political—it was structural.
When the system decides speed matters, it moves.
Now imagine applying even a fraction of that urgency to Lyme disease—a condition that remains underfunded despite affecting hundreds of thousands of Americans each year.
Many patients are misdiagnosed or diagnosed late and labeled with fibromyalgia, chronic fatigue, depression, or anxiety alone.
For patterns of misdiagnosis, see Lyme disease misdiagnosis.
We can—and should—do better.
What Adequate Funding Could Achieve
If Lyme disease were prioritized appropriately, progress could accelerate significantly.
- Improved diagnostic testing, particularly for later-stage disease
- Investment in persistent infection and co-infections such as Babesia and Bartonella
- Federal support for new therapeutics
- Research into neurologic, psychiatric, and autoimmune effects
- Improved physician education and training
- Sustained public education on early recognition and prevention
The Human Cost of Underfunding
When Lyme disease is underfunded, patients fall through the cracks.
Many spend years searching for a diagnosis. Those who develop post-treatment Lyme disease syndrome (PTLDS) often face the longest delays and the fewest options.
Some are treated for the wrong condition. Others are told their symptoms are psychological or exaggerated.
Yet when diagnosis is made and appropriate treatment begins, many patients improve.
Not overnight. Not without setbacks. But there is progress.
Now imagine if that healing could begin sooner.
It’s Time to Go Faster
Lyme disease has already taken too much—time, health, opportunity, and hope.
Recent public health responses have shown what is possible when speed, coordination, and funding align.
Lyme disease can no longer remain underfunded while patients continue to suffer.
Every day we wait is another day someone falls through the cracks.
And every step forward brings us closer to a future where patients receive timely diagnosis, appropriate treatment, and a real chance at recovery.
Frequently Asked Questions
Is Lyme disease underfunded?
Yes. It receives significantly less research funding than other conditions with similar prevalence and disability burden.
Why is Lyme disease underfunded?
Factors include historical skepticism, fragmented advocacy, and competition for research funding.
What would more funding accomplish?
Better diagnostics, research into persistent illness, improved treatments, and stronger physician education.
How can I advocate?
Contact representatives, support advocacy groups, and raise awareness.
Did COVID-19 change research expectations?
Yes. It showed that accelerated progress is possible when urgency and coordination align.
Resources
- NIH Research Portfolio. Funding estimates, 2024.
- CDC Lyme disease surveillance data, 2024.
- DeLong A et al. BMC Public Health, 2019.
- Johnson L et al. PeerJ, 2014.
Related Reading
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
